Grace Net Working Capital from 2010 to 2026
| GRCE Stock | 3.48 0.20 5.43% |
Net Working Capital | First Reported 2010-12-31 | Previous Quarter 18.7 M | Current Value 27.5 M | Quarterly Volatility 17.7 M |
Check Grace Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Grace Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 K, Interest Expense of 318.8 K or Other Operating Expenses of 17 M, as well as many indicators such as Price To Sales Ratio of 35.86, Dividend Yield of 0.0 or PTB Ratio of 0.39. Grace financial statements analysis is a perfect complement when working with Grace Therapeutics Valuation or Volatility modules.
Grace | Net Working Capital | Build AI portfolio with Grace Stock |
Analyzing Grace Therapeutics's Net Working Capital over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Working Capital has evolved provides context for assessing Grace Therapeutics's current valuation and future prospects.
Latest Grace Therapeutics' Net Working Capital Growth Pattern
Below is the plot of the Net Working Capital of Grace Therapeutics over the last few years. It is Grace Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Grace Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Working Capital | 10 Years Trend |
|
Net Working Capital |
| Timeline |
Grace Net Working Capital Regression Statistics
| Arithmetic Mean | 48,583,704 | |
| Geometric Mean | 44,586,014 | |
| Coefficient Of Variation | 36.38 | |
| Mean Deviation | 15,800,266 | |
| Median | 60,793,000 | |
| Standard Deviation | 17,675,090 | |
| Sample Variance | 312.4T | |
| Range | 42.1M | |
| R-Value | (0.83) | |
| Mean Square Error | 102.1T | |
| R-Squared | 0.69 | |
| Significance | 0.000033 | |
| Slope | (2,915,285) | |
| Total Sum of Squares | 4998.5T |
Grace Net Working Capital History
About Grace Therapeutics Financial Statements
Grace Therapeutics stakeholders use historical fundamental indicators, such as Grace Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Although Grace Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Grace Therapeutics' assets and liabilities are reflected in the revenues and expenses on Grace Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Grace Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 18.7 M | 27.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Grace Therapeutics is a strong investment it is important to analyze Grace Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics' future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:Check out the analysis of Grace Therapeutics Correlation against competitors. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.